Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma
Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05185544
Collaborator
(none)
50
36
Study Details
Study Description
Brief Summary
Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma
Anticipated Study Start Date
:
Jan 1, 2022
Anticipated Primary Completion Date
:
Dec 31, 2024
Anticipated Study Completion Date
:
Dec 31, 2024
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma |
Other: Neoadjuvant pemetrexed and cisplatin chemotherapy
neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
|
Outcome Measures
Primary Outcome Measures
- Tumor Regression Grade [1-2 Weeks after enrollment (after Surgery)]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
- Aged between 18 and 75 years;
-
- Lung adenocarcinoma;
-
- The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy
-
4 .The patient is able to understand and comply with the study and has provided written informed consent.
Exclusion Criteria:
-
- Patients with a history of lung surgery;
-
- Postoperative pathology showed non-primary lung cancer;
-
- Patients with a history of other tumors;
-
- Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
-
- Unable to cooperate with the researchers because of dementia or cognitive decline
-
- Other situations that are not in conformity with the standards and requirements of this trial.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Shanghai Zhongshan Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT05185544
Other Study ID Numbers:
- B2021-Zhan
First Posted:
Jan 11, 2022
Last Update Posted:
Jan 11, 2022
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: